Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of Glx Biomarker for NRX-101 in Bipolar Depression
NCT03402152Phase 3Completed
- Sponsor
- NRx Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of d-cycloserine + lurasidone in bipolar disorder (BD), sponsored by NRx Pharmaceuticals. Started Nov 2018; status: completed.
02
Drugs
d-cycloserine + lurasidone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03402152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402152.